BRAF and cancer: In melanomas, the mutation of valine to glutamic acid at amino acid 600 in BRAF (BRAFV600E) occurs in more than 50% of patients, and can boost kinase activity and constitutively promote the activation of MEK/ERK signaling, which endows cancer cells with increased proliferation, survival, and metastasis1–4.